PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
PharmAla Biotech, through its joint venture Cortexa, has become the first to supply GMP Psilocybin for therapeutic use in Australia under the TGA’s Authorized Prescriber Scheme, following its prior introduction of MDMA. This milestone establishes the company as a key player in the Australian market, supplying both compounds for clinical trials and authorized prescriptions. PharmAla’s commitment to advancing treatment options includes supporting patients and prescribers in Australia and Canada, leveraging its unique position as a provider of clinical-grade MDMA outside clinical trials.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.
